Who owns Janux Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of JANX from SEC Form 13F filings across 197 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 197 institutions disclosed 60.8M shares of Janux Therapeutics, Inc. worth $933.4M — about 96.6% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
197
13F holders
$933.4M
value, 2026 filers
96.6%
of shares outstanding (60.8M sh)
41
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of JANX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 11.2M | $171.9M | 1.5% | 17.8% | 0.0% |
| 2 | BlackRock, Inc. | 6.1M | $94.2M | 0.0% | 9.7% | +12.9% |
| 3 | Prosight Management, LP | 3.8M | $58.4M | 10.1% | 6% | +7.2% |
| 4 | STATE STREET CORP | 3.0M | $46.2M | 0.0% | 4.8% | +22.0% |
| 5 | FMR LLC | 2.4M | $37.1M | 0.0% | 3.8% | -4.8% |
| 6 | FEDERATED HERMES, INC. | 2.4M | $36.1M | 0.1% | 3.7% | +4241.2% |
| 7 | Point72 Asset Management, L.P. | 2.0M | $30.6M | 0.0% | 3.2% | +72.5% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $28.5M | 0.0% | 3% | +2.5% |
| 9 | TCG Crossover Management, LLC | 1.8M | $27.5M | 0.7% | 2.8% | 0.0% |
| 10 | Alyeska Investment Group, L.P. | 1.6M | $25.3M | 0.1% | 2.6% | +2.9% |
| 11 | WELLINGTON MANAGEMENT GROUP LLP | 1.5M | $23.2M | 0.0% | 2.4% | -5.7% |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $20.4M | 0.0% | 2.1% | +3.1% |
| 13 | TWO SIGMA INVESTMENTS, LP | 1.2M | $18.5M | 0.0% | 1.9% | +939.8% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.2M | $18.5M | 0.0% | 1.9% | +5.0% |
| 15 | CITADEL ADVISORS LLC | 1.2M | $18.4M | 0.0% | 1.9% | +240.9% |
| 16 | ALGERT GLOBAL LLC | 1.1M | $17.1M | 0.2% | 1.8% | +150.5% |
| 17 | D. E. Shaw & Co., Inc. | 1.1M | $16.8M | 0.0% | 1.7% | +1014.4% |
| 18 | GOLDMAN SACHS GROUP INC | 952,675 | $14.6M | 0.0% | 1.5% | +58.2% |
| 19 | BANK OF AMERICA CORP /DE/ | 910,460 | $14.0M | 0.0% | 1.4% | +13.6% |
| 20 | MORGAN STANLEY | 836,966 | $12.9M | 0.0% | 1.3% | +18.9% |
| 21 | Nantahala Capital Management, LLC | 809,914 | $12.4M | 0.4% | 1.3% | 0.0% |
| 22 | Qube Research & Technologies Ltd | 702,057 | $10.8M | 0.0% | 1.1% | +256.1% |
| 23 | Squarepoint Ops LLC | 532,321 | $8.2M | 0.0% | 0.8% | -11.9% |
| 24 | ORBIMED ADVISORS LLC | 524,700 | $8.1M | 0.1% | 0.8% | -46.7% |
| 25 | MILLENNIUM MANAGEMENT LLC | 504,544 | $7.7M | 0.0% | 0.8% | +30.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.